Actuate Therapeutics Inc

ACTU · Nasdaq

Actuate Therapeutics Inc (ACTU) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Actuate Therapeutics Inc in 2026. The next earnings report is expected on September 2, 2026.

Scheduled earnings dates

02 Sep 2026 02 Dec 2026

Earnings calendar

Next earnings date

02 Sep 2026

In 13 days

EPS estimate

-0.20

Revenue estimate

Past earnings

Date	EPS actual	Revenue actual	1d	5d	30d
14 Aug 2026	— estimate -0.21	— estimate 0	+2.37%	-2.41%	+4.37%
03 Jun 2026	— estimate -0.21	— estimate 0	+2.37%	-2.41%	+4.37%
14 May 2026	-0.24 (0.0%) estimate -0.24	0 estimate 0	+2.37%	-2.41%	+4.37%
26 Mar 2026	-0.25 (-0.9%) estimate -0.24	0 estimate 0	+2.37%	-2.41%	+4.37%
25 Feb 2026	-0.24 (+0.7%) estimate -0.24	0 estimate 0	+2.37%	-2.41%	+4.37%

14 Aug 2026

EPS actual

—

estimate -0.21

Revenue actual

—

estimate 0

Price reaction

+2.37%

-2.41%

30d

+4.37%

03 Jun 2026

EPS actual

—

estimate -0.21

Revenue actual

—

estimate 0

Price reaction

+2.37%

-2.41%

30d

+4.37%

14 May 2026

EPS actual

-0.24 (0.0%)

estimate -0.24

Revenue actual

estimate 0

Price reaction

+2.37%

-2.41%

30d

+4.37%

26 Mar 2026

EPS actual

-0.25 (-0.9%)

estimate -0.24

Revenue actual

estimate 0

Price reaction

+2.37%

-2.41%

30d

+4.37%

25 Feb 2026

EPS actual

-0.24 (+0.7%)

estimate -0.24

Revenue actual

estimate 0

Price reaction

+2.37%

-2.41%

30d

+4.37%

Beat Miss usd

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Sector: Healthcare
Industry: Biotechnology
Country: United States
Exchange: Nasdaq
CEO: Daniel Schmitt
Employees: 10
IPO date: 13 Aug 2024
ISIN: US0050831009
Website: actuatetherapeutics.com

Frequently asked questions

When does Actuate Therapeutics Inc (ACTU) next report earnings?

Actuate Therapeutics Inc (ACTU) is scheduled to report earnings on September 2, 2026.

What was Actuate Therapeutics Inc's most recent earnings date?

Actuate Therapeutics Inc (ACTU) last reported earnings on August 14, 2026.

Where is Actuate Therapeutics Inc stock listed?

Actuate Therapeutics Inc (ACTU) is listed on Nasdaq.